Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52152 | 1.00 | GBA1 (0.47) | GBA1FUCA1CYP2D6LTA4HS1PR1 | |
| SCHEMBL63432 | 0.85 | FUCA1 (0.58) | GBA1FUCA1CYP2D6S1PR1S1PR5 | |
| SCHEMBL51716 | 0.85 | FUCA1 (0.58) | GBA1FUCA1CYP2D6S1PR1S1PR5 | |
| SCHEMBL8790984 | 0.83 | LTA4H (0.56) | GBA1FUCA1CYP2D6LTA4HS1PR1 | |
| SCHEMBL3582865 | 0.83 | FUCA1 (0.63) | GBA1FUCA1CYP2D6S1PR1S1PR5 | |
| SCHEMBL20799625 | 0.77 | FUCA1 (0.49) | FUCA1LTA4HSIGMAR1 | |
| SCHEMBL20494682 | 0.77 | GBA1 (0.44) | GBA1FUCA1SIGMAR1 | |
| SCHEMBL20495014 | 0.77 | GBA1 (0.44) | GBA1FUCA1SIGMAR1 | |
| SCHEMBL20495013 | 0.77 | GBA1 (0.44) | GBA1FUCA1SIGMAR1 | |
| SCHEMBL5640368 | 0.76 | CYP2D6 (0.65) | GBA1FUCA1CYP2D6SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | GBA1 2972/4885FUCA1 2329/4885CYP2D6 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.